These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 10664542)

  • 1. Dose-dependency in local disposition of 5-fluorouracil under non-steady-state condition in rat liver.
    Higashimori M; Yamaoka K; Nakagawa T
    J Pharm Sci; 2000 Jan; 89(1):100-7. PubMed ID: 10664542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis program based on finite element method, MULTI(FEM), for evaluation of dose-dependent local disposition of drug in liver.
    Fukumura K; Yamaoka K; Higashimori M; Nakagawa T
    J Pharm Sci; 1999 May; 88(5):538-43. PubMed ID: 10229646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative evaluation of capacity-limited hepatobiliary transport based on hepatocellular diffusion model by MULTI(FEM).
    Higashimori M; Yamaoka K; Fujitani S; Nakagawa T
    J Pharmacokinet Pharmacodyn; 2001 Oct; 28(5):415-44. PubMed ID: 11768289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic analysis program based on tank-in-series model, MULTI(TIS), for evaluation of capacity-limited local disposition.
    Fukumura K; Yamaoka K; Higashimori M; Nakagawa T
    Biol Pharm Bull; 1998 Dec; 21(12):1338-43. PubMed ID: 9881650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonlinear pharmacokinetics of 5-fluorouracil in rats.
    Jarugula VR; Lam SS; Boudinot FD
    J Pharm Sci; 1997 Jun; 86(6):756-8. PubMed ID: 9188061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Metabolic Inhibitors on the Hepatic Disposition of 5-Fluorouracil after Application to the Rat Liver Surface.
    Shimokawa K; Wakasugi K; Tomonaga R; Utsunomiya K; Miyamoto H; Fumoto S; Nishida K
    Biol Pharm Bull; 2016; 39(3):361-7. PubMed ID: 26934928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of perfusion rate on the local disposition of cefixime in liver perfusion system based on two-compartment dispersion model.
    Yano Y; Yamaoka K; Yasui H; Nakagawa T
    Drug Metab Dispos; 1991; 19(6):1022-7. PubMed ID: 1687006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
    Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
    Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of capacity-limited first-pass effect through liver by three-points sampling in portal and hepatic veins and systemic artery.
    Ueda S; Yamaoka K; Yui J; Shigematsu A; Nakagawa T
    Pharm Res; 2002 Jun; 19(6):852-7. PubMed ID: 12134957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose and flow dependence of 5-fluorouracil elimination by the isolated perfused rat liver.
    Warren BS; LaCreta FP; Kornhauser DM; Williams WM
    Cancer Res; 1987 Oct; 47(20):5261-5. PubMed ID: 3652033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of vasomodulators and tumor transplantation on the disposition of 5-fluorouracil after application to the liver surface in rats.
    Kodama Y; Horishita M; Tokunaga A; Miyamoto H; Fumoto S; Sasaki H; Nakamura J; Nishida K
    Biopharm Drug Dispos; 2017 Sep; 38(6):367-372. PubMed ID: 28239866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice.
    Jin Y; Li J; Rong LF; Lü XW; Huang Y; Xu SY
    Acta Pharmacol Sin; 2005 Feb; 26(2):250-6. PubMed ID: 15663907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moment analysis of intestinal first-pass metabolism by portal-systemic concentration difference in single conscious rat using 5'-deoxy-5-fluorouridine and 5-fluorouracil as model drug system.
    Sawai Y; Yamaoka K; Takemura A; Nakagawa T
    J Pharm Sci; 1997 Nov; 86(11):1269-72. PubMed ID: 9383738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of viscous additives on the absorption and hepatic disposition of 5-fluorouracil (5-FU) after application to liver surface in rats.
    Kodama Y; Horishita M; Fumoto S; Mine T; Miyamoto H; Yoshikawa N; Hirata H; Sasaki H; Nakamura J; Nishida K
    J Pharm Pharmacol; 2012 Oct; 64(10):1438-44. PubMed ID: 22943174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
    Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
    Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasopressin selectively increases 5-fluorouracil uptake by colorectal liver metastases following hepatic artery bolus infusion.
    Dietz DW; Casillas S; Jones SC; Milsom JW
    J Surg Res; 1998 Jul; 77(2):150-6. PubMed ID: 9733602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice.
    Innocenti F; Danesi R; Bocci G; Natale G; Del Tacca M
    Toxicol Appl Pharmacol; 2005 Mar; 203(2):106-13. PubMed ID: 15710171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic fibrosis does not affect the pharmacokinetics of 5-fluorouracil in rats.
    Nagata M; Hidaka Y; Hatakeyama K; Kawano Y; Iwakiri T; Okumura M; Arimori K
    Biopharm Drug Dispos; 2011 Mar; 32(2):126-30. PubMed ID: 21341281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.